Focal segmental glomerulosclerosis: genetic analysis and target therapy

Authors

  • O.O. Melnyk Tertiary Medical Center “Optima-Pharm”, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.7.1.2018.122218

Keywords:

focal segmental glomerulosclerosis, podocytes, protein mutations, treatment

Abstract

With focal segmental glomerulosclerosis (FSGS) is associated with initial damage of podocytes. Human genetic studies over the last few years have shown that FSGS is primarily a podocytopathia with more than 20 mutated genes involved in the pathogenesis of this disease. Nephrin (NPHS1 gene) together with the podocine (NPHS2 gene) are the main proteins of podocyts slit diaphragm. Autosomal-recessive mutations of NPHS1, NPHS2 are associated with more severe condition of patients, which is manifested by early proteinuria and end-stage renal disease compared with autosomal-dominant mutations of INF2, TRPC6 and ACTN4. For initial treatment of FSGS, Kidney Disease Improving Global Outcomes (KDIGO) 2012 recommends the use of corticosteroid and immunosuppressive therapy.

Downloads

Download data is not yet available.

References

Braden GL, Mulhern JG, O’Shea MH, Nash SV, Ucci Jr AA, Germain MJ. Changing incidence of glomerular diseases in adults. Am J Kidney Dis.2000;35(5):878-83.

Fahr T, author. Pathologische Anatomie des Morbus Brightii [Pathological anatomy of Brightii's disease]. In: Fahr T, Gruber GB, Koch M, Lubarsch O, Stoerk O, authors. Harnorgane Männliche Geschlechtsorgane [Urinary organs Male genitalia]. Wien: Springer-Verlag Wien; 1925. 156-472pp. doi: 10.1007/978-3-7091-3054-4. (in German).

Rich AR. A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp. 1957 Apr;100(4):173-86. PMID: 13426687.

D’Agati V, Fogo A, Bruijn J, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004 Feb;43(2):368-82. PMID: 14750104.

Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults. Kidney Int Suppl (2011). 2012 Jun;2(2):181-185. doi: 10.1038/kisup.2012.19.

Basgen JM, Steffes MW, Stillman AE, Mauer SM. Estimating glomerular number in situ using magnetic resonance imaging and biopsy. Kidney Int. 1994;45(6):1668-72. PMID: 7933814.

Greka A, Mundel P. Cell biology and pathology of podocytes. Annu Rev Physiol. 2012;74:299-323. doi: 10.1146/annurev-physiol-020911-153238.

Barisoni L, Schnaper HW, Kopp JB. Advance in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Arch Pathol Lab Med. 2009 Feb;133(2):201-16. doi: 10.1043/1543-2165-133.2.201.

Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor ransgene. J Am Soc Nephrol. 2005;16(10):2941-52. doi:10.1681/ASN.2005010055.

Hildebrandt F. Genetic kidney diseases. Lancet. 2010 Apr 10;375(9722):1287-95. doi: 10.1016/S0140-6736(10)60236-X.

Sánchez de la Nieta MD, Arias LF, de la Torre M, et al. Familial focal and segmentary hyalinosis. Nefrologia. 2003;23(2):172-6. PMID: 12778884. (in Spanish).

Schell C, Huber TB. New players in the pathogenesis of focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2012 Sep;27(9):3406-12. doi: 10.1093/ndt/gfs273.

Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein–nephrin–is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1(4):575-82. PMID: 9660941.

Ahvenainen EK, Hallman N, Hjelt L. Nephrotic syndrome in newborn and young infants. Ann Paediatr Fenn. 1956;2(3):227-241. PMID: 13373132.

Khoshnoodi J, Sigmundsson K, Ofverstedt LG, et al. Nephrin promotes cell–cell adhesion through homophilic interactions. Am J Pathol. 2003 Dec;163(6):2337-46. doi:10.1016/S002-9440(10)63590-0.

Pätäri-Sampo A, Ihalmo P, Holthöfer H. Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm. Ann Med. 2006;38(7):483-492. doi:org/10.1080/07853890600978149.

Barisoni L, Mundel P. Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol. 2003;23(5):353-360. doi: 10.1159/000072917.

Lenkkeri U, Mannikko M, McCready P et al. Structure of the gene for congenital nephrotic syndrome of the Finnish type (NPHS1) and characterization of mutations. Am J Hum Genet. 1999;64(1):51-61. PMID: 9915943.

Beltcheva O, Martin P, Lenkkeri U, Tryggvason K. Mutation spectrum in the nephrin gene (NPHS1) in congenital nephrotic syndrome. Hum Mutat. 2001;17(5):368-373. doi:10.1002/humu.1111.

Lahdenkari AT, Kestila M, Holmberg C, Koskimies O, Jalanko H. Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). Kidney Int. 2004 May;65(5):1856-63. doi:10.1111/j.1523-1755.2004.00583.x.

Heeringa SF, Vlangos CN, Chernin, G, et al. Thirteen novel NPHS1 mutations in a large cohort of children with congenital nephrotic syndrome. Nephrol Dial Transplant. 2008;23(11):3527-3533. doi:10.1093/ndt/gfn271.

Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics. 2007 Apr;119(4):e907-19. doi:10.1542/peds.2006-2164.

Philippe A, Nevo F, Esquivel EL, et al. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2008 Oct;19(10):1871-8. doi: 10.1681/ASN.2008010059.

Laakkonen H, Lönnqvist T, Uusimaa J, et al. Muscular dystonia and athetosis in six patients with congenital nephrotic syndrome of the Finnish type (NPHS1). Pediatr Nephrol. 2006 Feb;21(2):182-9. doi :10.1007/s00467-005-2116-1.

Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nature Genetics. 2000;24(4):349-354. doi:10.1038/74166.

Caridi G, Bertelli R, Di Duca M, et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol. 2003 May;14(5):1278-86. doi: 10.1097/01.ASN.0000060578.79050.E0.

Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (Podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol. 2004 Mar;15(3):722-32. doi: 10.1097/01.ASN.0000113552.59155.72.

Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 2004 Aug;66(2):571-9. DOI: 10.1111/j.1523-1755.2004.00776.x.

Roselli S, Heidet L, Sich M, et al. Early glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol Cell Biol. 2004 Jan;24(2):550-60. PMID: 14701729.

Pereira AC, Pereira AB, Mota GF, et al. NPHS2 R229Q functional variant is associated with micro-albuminuria in the general population. Kidney Int. 2004 Mar;65(3):1026-30. doi:10.1111/j.1523-1755.2004.00479.x.

Huber TB, Simons M, Hartleben B, et al. Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet. 2003 Dec 15;12(24):3397-405. doi: 10.1093/hmg/ddg360.

Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis. 2003 Jun;41(6):1314-21. PMID: 12776285.

Caridi G, Perfumo F, Ghiggeri GM. NPHS2 (Podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatr Res. 2005 May;57(5 Pt 2):54R-61R. doi:10.1203/01.PDR.0000160446.01907.B1.

Shih NY, Li J, Cotran R Mundel P, Miner JH, Shaw AS. CD2AP localizes to the slit diaphragm and binds to nephrin via a novel C-terminal domain. Am J Pathol. 2001 Dec;159(6):2303-8. doi:10.1016/S0002-9440(10)63080-5.

Schwarz K, Simons M, Resier J, et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest. 2001 Dec;108(11):1621-9. doi:10.1172/JC112849.

Shih NY, Li J, Karpitskii V, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 1999 Oct 8;286(5438):312-5. PMID: 10514378.

Huber TB, Hartleben B, Kim J, et al. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol. 2003 Jul;23(14):4917-28. doi:10.1128/MCB.23.14.4917-4928.2003.

Lowik MM, Groenen PJ, Pronk I, et al. Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int. 2007 Nov;72(10):1198-203. doi: 10.1038/sj.ki.5002469.

Harteneck C, Plant TD, Schultz G. From worm to man: Three subfamilies of TRP channels. Trends Neurosci. 2000 Apr;23(4):159-66. PMID: 10717675.

Montell C, Birnbaumer L, Flockerzi V, et al. A unified nomenclature for the superfamily of TRP cation channels. Mol Cell. 2002 Feb;9(2):229-31. PMID: 11864597.

Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermann T, Schultz G. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63. doi:10.1038/16711.

Reiser J, Polu KR, Möller CC, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet. 2005 Jul;37(7):739-44. doi:10.1038/ng1592.

Winn MP, Conlon PJ, Lynn KL, Et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science. 2005 Jun 17;308(5729):1801-4. doi:10.1126/science.1106215.

Santín S, Ars E, Rossetti S, Salido E. et al. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2009 Oct;24(10):3089-96. doi: 10.1093/ndt/gfp229.

Zhu B, Chen N, Wang ZH, et al. Identification and functional analysis of a novel TRPC6 mutation associated with late onset familial focal segmental glomerulosclerosis in Chinese patients. Mutat Res. 2009 May 12;664(1-2):84-90. doi: 10.1016/j.mrfmmm.2008.11.021.

Gigante M, Caridi G, Montemurno E, et al. TRPC6 mutations in children with steroid-resistant nephrotic syndrome and atypical phenotype. Clin J Am Soc Nephrol. 2011 Jul;6(7):1626-34. doi: 10.2215/CJN.07830910.

Michaud JL, Lemieux LI, Dube M, Vanderhyden BC, Robertson SJ, Kennedy CR. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha-actinin-4. J Am Soc Nephrol. 2003 May;14(5):1200-11. PMID: 12707390.

Weins A, Kenlan P, Herbert S, et al. Mutational and biological analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol. 2005 Dec;16(12):3694-701. doi: 10.1681/ASN.2005070706.

Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000 Mar;24(3):251-6. doi: 10.1038/73456.

Weins A, Schlondorff J, Nakamura F, et al. Disease-associated mutant alpha-actinin-4 reveals a mechanism for regulating its F-actin-binding affinity. Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16080-5. doi:10.1073/pnas.0702451104.

Zhu L, Jiang R, Aoudjit L, Jones N, Takano T. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011 Sep;22(9):1621-30. doi: 10.1681/ASN.2010111146.

Sun H, Schlondorff J, Higgs HN, Pollak MR. Inverted formin 2 regulates actin dynamics by antagonizing Rho/diaphanous-related formin signaling. J Am Soc Nephrol. 2013 May;24(6):917-29. doi: 10.1681/ASN.2012080834.

Brown EJ, Schlondorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet. 2010 Jan;42(1):72-6. doi: 10.1038/ng.505.

Gee HY, Saisawat P, Ashraf S, et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest. 2013 Aug;123(8):3243-53. doi: 10.1172/JCI69134.

Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature. 1990 Feb 22;343(6260):774-8. doi: 10.1038/343774a0.

McTaggart SJ, Algar E, Chow CW, Powell HR, Jones CL. Clinical spectrum of Denys-Drash and Frasier syndrome. Pediatr Nephrol. 2001 Apr;16(4):335-9. PMID: 11354777.

Zenker M, Aigner T, Wendler O, et al. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet. 2004 Nov 1;13(21):2625-32. doi:10.1093/hmg/ddh284.

Pozzi A, Jarad G, Moeckel GW, et al. Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity. Dev Biol. 2008 Apr 15;316(2):288-301. doi: 10.1016/j.ydbio.2008.01.022.

Hasselbacher K, Wiggins RC, Matejas V, et al. Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Kidney Int. 2006 Sep;70(6):1008-12. doi: 10.1038/sj.ki.5001679.

Berkovic SF, Dibbens LM, Oshlack A, et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet. 2008 Mar;82(3):673-84. doi: 10.1016/j.ajhg.2007.12.019.

Settembre C, Fraldi A, Rubinsztein DC, Ballabio A. Lysosomal storage diseases as disorders of autophagy. Autophagy. 2008 Jan;4(1):113-4. doi: 10.4161/auto.5227.

Lowik MM, Hol FA, Steenbergen EJ, Wetzels JF, van den Heuvel LP. Mitochondrial tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2005 Feb;20(2):336-41. doi:10.1093/ndt/gfh546.

Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol. 2007 Oct;18(10):2773-80. doi: 10.1681/ASN.2006080833.

Lopez LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet. 2006 Dec;79(6):1125-9. doi:10.1086/510023.

Heeringa SF, Chernin G, ChakiM, et. al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest. 2011 May;121(5):2013-24. doi: 10.1172/JCI45693.

Beaudreuil S, Lorenzo HK, Elias M, Nnang Obada E, Charpentier B, Durrbach A. Optimal management of primary focal segmental glomerulosclerosis in adults. Int J Nephrol Renovasc Dis. 2017 May 10;10:97-107. doi: 10.2147/IJNRD.S126844 .

Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults. Kidney Int Suppl (2011). 2012 Jun;2(2):181-185. doi: 10.1038/kisup.2012.19.

Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005 Apr;16(4):1061-8. doi:10.1681/ASN.2004070593.

Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol. 1994;5(4):1049-1056. PMID: 7849244.

Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–application to the individual patient. Kidney Int. 2012 Oct;82(8):840-56. doi: 10.1038/ki.2012.280.

Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008 Sep;14(9):931-8. doi: 10.1038/nm.1857.

Okada T, Matsumoto H, Nagaoka Y, et al. Clinical evaluation of chronic nephrotoxicity of long-term cyclosporine A treatment in adult patients with steroid-dependent nephrotic syndrome. Nephrology (Carlton). 2011 Mar;16(3):319-25. doi: 10.1111/j.1440-1797.2010.01425.x.

Westhoff TH, Schmidt S, Zidek W, Beige J, van der Giet M. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol. 2006 Jun;65(6):393-400.

Ren H, Shen P, Li X, Pan X, Zhang W, Chen N. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol. 2013;37(1):84-90. doi: 10.1159/000346256.

Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993;8(12):1326-1332. PMID: 8159300.

Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83(3):511-516. doi:10.1038/ki.2012.444.

Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56(6):2220-2226. DOI:10.1046/j.1523-1755.1999.00778.x.

Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004;19(12):3062-3067.

doi:10.1093/ndt/gfh536.

Gulati S, Pokhariyal S, Sharma RK, et al. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 2001;16(10):2013–2017. PMID: 11572890.

Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46. doi:10.1126/scitranslmed.3002231.

Joy MS, Gipson DS, Powell L, et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010;55(1):50-60. doi:10.1053/j.ajkd.2009.08.019.

Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011;79(11):1236–1243. doi:10.1038/ki.2011.33.

Mittal T, Dedhia P, Roy-Chaudhury P, et al. Complete remission of posttransplantation recurrence of focal segmental glomerulosclerosis with the use of adrenocorticotrophic hormone gel: case report. Transplant Proc. 2015 Sep;47(7):2219-22. doi: 10.1016/j.transproceed.2015.07.013.

Fowler SM, Kon V, Ma L, Richards WO, Fogo AB, Hunley TE. Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol. 2009;24(4):851-5. doi: 10.1007/s00467-008-1024-6.

Lescure FX, Flateau C, Pacanowski J, et al. HIV-associated kidney glomerular diseases:changes with time and HAART. Nephrol Dial Transplant. 2012 Jun;27(6):2349-55. doi: 10.1093/ndt/gfr676.

Downloads

Published

2021-09-08

How to Cite

Melnyk, O. (2021). Focal segmental glomerulosclerosis: genetic analysis and target therapy. KIDNEYS, 7(1), 35–49. https://doi.org/10.22141/2307-1257.7.1.2018.122218

Issue

Vol. 7 No. 1 (2018)

Section

Looking at the problem

License

Copyright (c) 2018 O.O. Melnyk

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.